2026 ICD-10-CM Diagnosis Code T80.810AExtravasation of vesicant antineoplastic chemotherapy, initial encounter

ICD-10-CM Codes›S00–T88›T80-T88›T80

ICD-10-CM T80.810A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T80.810A is a billable ICD-10-CM diagnosis code for extravasation of vesicant antineoplastic chemotherapy, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 314 through 316. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Complication of other surgical or medical care, injury, initial encounter; and Conditions due to neoplasm or the treatment of neoplasm.

Code Identity

ICD-10-CM Code
T80.810A
Billable Status
Yes — Valid for Submission
Code Describes
Extravasation of vesicant antineoplastic chemotherapy, initial encounter
Short Description
Extravasation of vesicant antineoplastic chemotherapy, init
Parent Code
T80.810
Extravasation of vesicant antineoplastic chemotherapy

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT80-T88Complications of surgical and medical care, not elsewhere classified
CategoryT80Complications following infusion, transfusion and therapeutic injection
This CodeT80.810AExtravasation of vesicant antineoplastic chemotherapy, initial encounter

Coding GuidelinesGuidance

The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ037
Complication of other surgical or medical care, injury, initial encounter
Default principal diagnosis: inpatient No · outpatient No
CCSR NEO074
Conditions due to neoplasm or the treatment of neoplasm
Default principal diagnosis: inpatient Yes · outpatient Yes

Convert T80.810A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
999.81 Extravstn vesicant chemo
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T80.810AOverview

Is T80.810A (Extravasation of vesicant antineoplastic chemotherapy) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report extravasation of vesicant antineoplastic chemotherapy, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T80.810A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for extravasation of vesicant antineoplastic chemotherapy, such as an emergency visit or first evaluation.

What MS-DRG does T80.810A group to?

When extravasation of vesicant antineoplastic chemotherapy, initial encounter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 314, 315, 316, with relative weights from 0.6821 to 2.0852 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of T80.810A?

Under the General Equivalence Mappings, extravasation of vesicant antineoplastic chemotherapy, initial encounter converts to ICD-9-CM 999.81 (extravstn vesicant chemo). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.